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PHeart Failure
Central Sleep Apnea, Right Ventricular
Dysfunction, and Low Diastolic Blood Pressure
Are Predictors of Mortality in Systolic Heart Failure
Shahrokh Javaheri, MD, Rakesh Shukla, PHD, Haoyue Zeigler, MS, Laura Wexler, MD
Cincinnati, Ohio
Objectives The purpose of this study was to determine whether central sleep apnea (CSA) contributes to mortality in pa-
tients with heart failure (HF).
Background Cheyne-Stokes breathing with CSA commonly occurs in patients with systolic HF. Consequences of CSA, includ-
ing altered blood gases and neurohormonal activation, could result in further left ventricular dysfunction. There-
fore, we hypothesized that CSA might contribute to mortality of patients with HF.
Methods We followed 88 patients with systolic HF (left ventricular ejection fraction 45%) with (n  56) or without
(n  32) CSA. The median follow-up was 51 months.
Results The mean (SD) of apnea-hypopnea index was significantly higher in patients with CSA (34  25/h) than those
without CSA (2  1/h). Most of these events were central apneas. In Cox multiple regression analysis, 3 of 24
confounding variables independently correlated with survival. The median survival of patients with CSA was 45
months compared with 90 months of those without CSA (hazard ratio  2.14, p  0.02). The other 2 variables
that correlated with poor survival were severity of right ventricular systolic dysfunction and low diastolic blood
pressure.
Conclusions In patients with systolic HF, CSA, severe right ventricular systolic dysfunction, and low diastolic blood pressure
might have an adverse effect on survival. (J Am Coll Cardiol 2007;49:2028–34) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.084a
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Heart failure (HF) is a prevalent syndrome with
poor prognosis. Identification of variables that
contribute to increased mortality and are treat-
able might lead to improvement in survival.
Cheyne-Stokes breathing (CSB) with central
sleep apnea (CSA) commonly occurs in pa-
ients with HF due to systolic dysfunction (1–5). Recurrent
pisodes of apnea (cessation of breathing) and hypopnea
decrease in breathing) followed by hyperpnea are associated
ith recurrent episodes of hypoxemia-reoxygenation, arous-
ls, and relatively large negative deflections in intrathoracic
ressure. These pathophysiological consequences of sleep
pnea-hypopnea might result in an imbalance in myocardial
xygen delivery/consumption ratio, activation of sympa-
hetic and other neurohormonal systems, and increased
ight and left ventricular afterload (6,7). Therefore, sleep
rom the Department of Veterans Affairs Medical Center, Cincinnati, Ohio; and the
epartments of Medicine and Environmental Health, University of Cincinnati
ollege of Medicine, Cincinnati, Ohio. This work was supported by grants from the
erit Review Program.f
Manuscript received November 9, 2006; revised manuscript received January 19,
007, accepted January 29, 2007.pnea could contribute to mortality of patients with sys-
olic HF.
Findley et al. (8) were the first to report that CSB/CSA
as associated with increased mortality in patients with
ystolic HF. However, several recent studies have reported
onflicting results (9–14), calling into question whether
SA contributes directly to the prognosis of HF or is
erely an epiphenomenon (15). The present report repre-
ents the largest and most systematic study of a cohort of
ell-defined patients with compensated congestive HF and
ystolic dysfunction, some with and some without CSA,
ho were followed at the Veterans Affairs Medical Center
n Cincinnati. The primary end point was all cause mortality
o determine whether CSB/CSA is an independent
redictor.
ethods
ithin the last several years, our laboratory has been involved
n a series of prospective studies of sleep apnea in patients with
table HF due to systolic dysfunction (left ventricular ejection
raction [LVEF] 45%) (2,16). Patients were recruited from
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May 22, 2007:2028–34 Sleep Apnea and Mortality in HFardiology and primary care clinics. These were patients with
ypical chronic congestive HF who had been treated in our
linics for a long time. At the time of recruitment, no
nformation was sought about symptoms or risks factors for
leep apnea. Patients were examined by the cardiologist inves-
igator to assure they were receiving adequate and stable
herapy for treatment of HF. Details have been published
reviously (2,16,17). Exclusion criteria were unstable angina;
nstable HF; interstitial lung disease; obstructive lung defect;
ntrinsic renal and liver disorders; use of morphine derivatives,
enzodiazepines, or theophylline; and presence of obstructive
leep apnea (see subsequent text).
For uniformity, only male patients were studied, because
emale patients are seldom referred to this center. This
rotocol was approved by the Institutional Review Board of
he University of Cincinnati Medical Center. Each patient
igned the consent form.
Of 114 eligible patients, 100 (88% recruitment) agreed to
articipate. The main reasons for refusal were unwillingness
o stay in the hospital for sleep studies or unwillingness to
ravel to the Veterans Affairs Medical Center because of
istance. The mean LVEF of 9 of the 14 non-participating
atients in whom data were available was 18  6%, which
s similar to that of the participants in the study. One
undred patients underwent polysomnography; 12 of them
ad predominantly obstructive sleep apnea and were ex-
luded. Therefore, a total of 88 patients are involved in this
eport.
The patients were admitted to the hospital for 2 consec-
tive nights. On the first night, the patients slept in the
leep laboratory and electrodes were placed for habituation
o the environment of the laboratory. Caffeinated products
ere proscribed. A detailed history including sleep habits
as obtained, and physical examination was performed by 1
uthor (S.J.). The following tests were also obtained: com-
lete blood count, serum electrolytes, blood urea nitrogen,
erum creatinine, digoxin level, radionuclide ventriculogra-
hy, arterial blood gases and pH, and pulmonary function
ests. Details have been published previously (2,16,17).
On the second night, polysomnography was performed
ith standard techniques as detailed previously (2,16,17).
e recorded electroencephalogram, electro-oculogram, and
hin electromyogram. Thoracoabdominal excursions and
aso-oral airflow (with a thermocouple) were measured
ualitatively, and arterial blood oxyhemoglobin saturation
as recorded with a pulse oximeter. These variables were
ecorded on a multichannel polygraph (Model 78D, Grass
nstrument Company, Quincy, Massachusetts).
Standard definitions were used for sleep-related disor-
ered breathing (18,19). An apnea was defined as cessation
f inspiratory airflow for 10 s or more. An obstructive apnea
as defined as the absence of airflow in the presence of rib
age and abdominal excursions. A central apnea was defined
s the absence of rib cage and abdominal excursions with
bsence of airflow. Hypopnea was defined as a discernible
eduction of airflow (or thoracoabdominal excursions) last- cng 10 s or more and associated
ith at least a 4% drop in arterial
xyhemoglobin saturation and/or
n arousal. An arousal was de-
ned as appearance of alpha wave
n electroencephalogram for at
east 3 s (19). Hypopneas were
efined as obstructive if thoraco-
bdominal excursions were out of
hase. The number of apneas and
ypopneas/h of sleep is referred to
s the apnea-hypopnea index
AHI). Similarly, the number of
rousals/h of sleep is the arousal
ndex. Polysomnograms were
cored blindly by 1 author (S.J.).
or patients with AHI 15/h, supplemental nocturnal
xygen was recommended; however, we do not know how
any of these patients received oxygen and who complied.
eceased patients were verified with Hospital Inquiry,
hich is an information database maintained by the Veter-
ns Affairs regional office.
tatistical analysis. The primary outcome variable was
urvival from the time of polysomnogram. Our key “explan-
tory” variable was CSA (yes/no) as defined by categorizing
HI. We used an AHI5/h to define presence of clinically
ignificant sleep apnea. This threshold has been used to
efine presence of clinically significant obstructive sleep
pnea (18). However, we also used other AHI thresholds for
nalysis of survival (see subsequent text).
To ascertain independent effect of CSA on patient’s
urvival, we identified potential confounders (i.e., variables
ssociated with both the key explanatory variable [AHI] and
he key outcome variable [time till death]) and covariates
i.e., variables associated with the outcome only). These
ariables included age, body mass index, heart rate, systolic
lood pressure, diastolic blood pressure, smoking status,
ew York Heart Association (NYHA) functional class,
ight ventricular ejection fraction (RVEF), LVEF, atrial
brillation, cause of HF (ischemic vs. idiopathic cardiomy-
pathy), time during sleep with oxygen saturation below
0%, minimal oxygen saturation during sleep, forced expi-
atory volume in 1 s (FEV1) percentage predicted, forced
ital capacity (FVC) percentage predicted, FEV1/FVC per-
entage predicted, diffusion capacity for carbon monoxide
ercentage predicted, partial pressure (P) arterial blood (a)
2, PaCO2, serum [K
], serum [Na], hemoglobin, and
igoxin level 1 nmol/l versus 1 nmol/l.
A univariate Cox proportional hazard regression was used
o obtain significant associations between continuous cofac-
ors and survival time. The log-rank test was used to
scertain significant association between survival time and
ategorical cofactors. Two-sample t test (p 0.10) was used
o ascertain whether significant difference existed between
he key predictor-CSA (dichotomous) and factors that were
Abbreviations
and Acronyms
AHI  apnea-hypopnea
index
CPAP  continuous
positive airway pressure
CSA  central sleep apnea
CSB  Cheyne-Stokes
breathing
HF  heart failure
LVEF  left ventricular
ejection fraction
RVEF  right ventricular
ejection fractionontinuous in nature. Chi-square test was used to obtain
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Sleep Apnea and Mortality in HF May 22, 2007:2028–34ssociation between CSA and categorical factors. Cox
roportional hazard multiple regression analysis was per-
ormed to determine whether significant difference existed
n survival between the patients with CSA and those
ithout CSA, after controlling for all identified confound-
rs and covariates in the model. Significant confounders
p 0.10) identified in the univariate analysis were included
n the starting model for the multivariate analyses. Back-
ard elimination procedure was used to identify final
educed model. All identified variables were included in the
odel, and nonsignificant covariates were removed with
ackward elimination according to a selection stay criterion
f 0.05. The hazard ratio and its 95% confidence interval for
urvival were used to assess the importance of confounders
nd covariates. This strategy allowed us to assess indepen-
ent impact of CSA on mortality after accounting for all
elevant and significant covariates and confounders of mor-
ality in this cohort of patients. Adjusted hazard ratio of
urvival and adjusted survival curves between patients with
nd without CSA was also calculated.
In addition to AHI threshold of 5/h, we also used AHI
utoff points of 10 or more, 15 or more, 20 or more, 25 or
ore, and 30 or more to define different patient groups with
SA and calculated hazard ratios of survival after adjusting
or potential confounders. Mean values  SD are reported.
ata were analyzed with SAS software for Windows version
(SAS Institute, Cary, North Carolina).
esults
escriptive characteristics and sleep-related breathing dis-
rders of the 2 groups of patients with and without CSA are
resented in Tables 1, 2, and 3. The average AHI of
atients with CSA was 34/h, and most of these events were
entral apneas. These events were associated with arousals,
esaturation, and decreased rapid eye movement sleep.
The median follow-up was 51 months with a 25th
ercentile of 21 and 75th percentile of 112 months. In
nivariate analysis, several of the 24 variables correlated with
urvival (Table 4). Systolic and diastolic blood pressures,
VEF, RVEF, and minimum saturation during sleep pos-
tively correlated with survival, whereas AHI, time below
aturation of 90%, heart rate, and NYHA functional class
II negatively correlated with survival. Serum digoxin 1
mol/l was associated with a short survival.
In multiple Cox proportional hazard regression analysis,
nly 3 variables were independently associated with survival.
fter adjusting for all significant cofactors, patients without
SA had significantly higher survival probability than
atients with CSA (hazard ratio  2.14, p  0.02) (Fig. 1).
he median survival time of patients without CSA and with
SA were 90 and 45 months, respectively (p 0.01) (Fig. 2).
he other 2 variables that independently correlated with
urvival were RVEF (hazard ratio  0.97, p  0.003) and
iastolic blood pressure (hazard ratio  0.96, p  0.02). pWhen mortality of patients with AHI 5/h was com-
ared with those with AHI categories of 5/h and 10/h,
0/h and 15/h, and 15/h, the survival of patients
ithout CSA was the longest and the respective hazard
atios were 1.52 (p  0.37), 3.07 (p  0.03), and 2.26 (p 
.02). We also compared the median survival of groups
elow and above various AHI cutoff points (Fig. 2). In all
ategories, the median survival was significantly longer for
atients below each threshold when compared with those
bove the threshold.
iscussion
he results show that in patients with systolic HF, the
resence of CSA defined as AHI of 5 or more /h is an
ndependent predictor of mortality (Fig. 1). We used an
HI of 5/h as the threshold for this analysis because this
hreshold is used to define presence of significant obstruc-
ive sleep apnea (18). After accounting for various con-
ounders, patients with AHI 5/h lived about twice as long
s patients with AHI 5/h (90 months vs. 45 months). The
xcess mortality of HF patients with CSA was also evident
hen various groups of different thresholds (below and
bove various AHI levels) were compared (Fig. 2).
It must be emphasized that the effect of CSA on survival
as present after adjustments for a large number of con-
ounders, such as LVEF, NYHA functional class, heart rate,
erum digoxin and sodium concentration, hemoglobin, and
ge, variables that have been shown to be associated with
emographic and Cardiovascular Parameters in 88art F ilure Patients With and Without Centralleep Apnea
Table 1
Demographic and Cardiovascular Parameters in 88
Heart Failure Patients With and Without Central
Sleep Apnea
Variable AHI <5/h AHI >5/h p Value
Number 32 56
Age, yrs 62 12 67 9 0.02
BMI, kg/m2 28 5 26 4 0.09
Systolic blood pressure, mm Hg 127 22 119 20 0.06
Diastolic blood pressure, mm Hg 72 10 70 10 0.09
Heart rate, beats/min 78 14 80 13 0.48
LVEF, % 27 9 22 8 0.006
RVEF, % 49 11 43 15 0.048
Atrial fibrillation, % 6 20 0.1
New York Heart Association functional
classification
Class I, % 25 9 0.09
Class II, % 53 55 0.09
Class III, % 22 36 0.09
Ischemic dilated cardiomyopathy, % 75 75 1.0
Idiopathic dilated cardiomyopathy, % 25 25 1.0
ACEI, % 88 93 0.6
Beta-blockers, % 9 11 0.8
Digoxin, % 78 71 0.8
Furosemide, % 78 84 0.4
CEI  angiotensin-converting enzyme inhibitor; AHI  apnea-hypopnea index; BMI  body mass
ndex; LVEF  left ventricular ejection fraction; RVEF  right ventricular ejection fraction.oor survival in patients with systolic HF.
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May 22, 2007:2028–34 Sleep Apnea and Mortality in HFThe results of this study are particularly important be-
ause previous studies of survival in patients with HF,
ncluding those considering the role of angiotensin-
onverting enzyme inhibitors or beta blockers, have not
outinely included sleep studies; therefore, the impact of
leep apnea on survival was not known.
However, there are a few studies of patients with HF in
hich sleep studies were performed to determine the effect
f sleep apnea on survival (8–14). The results have been
ivergent. A major criticism in most previous studies is the
mall number of patients, either in the CSA or in the
ontrol group. Also, some of the studies combined cardiac
Sleep-Related Breathing Disorders in 88 HeartFailure Pati nts Wi or Without Ce tral Sleep A
Table 2 Sleep-Related Breathing Disorders iFailure Patients With or Without Ce
Variable
Number of patients
AHI, n/h
Central apnea index, n/h
Obstructive apnea index, n/h
Central AHI, n/h
Obstructive AHI, n/h
Total time in bed, min
Total sleep time, min
Sleep stage 1, % TST
Sleep stage 2, % TST
Sleep stages 3 and 4, % TST
Rapid eye movement sleep, % TST
Non-rapid eye movement sleep, % TST
Arousals, n/h
Arterial oxyhemoglobin saturation during sleep, %
Baseline
Minimum value
90%, % TST
AHI  apnea-hypopnea index; TST  total sleep time.
ulmonary Function Tests and Selective Blood Testsn 88 P tients W th or Without Central Sleep Apnea
Table 3 Pulmonary Function Tests and Selective Blood Testsin 88 Patients With or Without Central Sleep Apnea
Variable AHI <5/h AHI >5/h p Value
FEV1, % 76 19 86 19 0.02
FVC, % 85 17 88 17 0.45
FEV1/FVC, % 89 11 97 12 0.003
DLCO, % 69 19 64 22 0.37
PaO2, mm Hg 78 11 86 9 0.002
PaCO2, mm Hg 39 5 37 4 0.02
pH 7.43 0.02 7.44 0.03 0.02
Hemoglobin, g% 14.4 2 14.1 1.6 0.52
Hematocrit, % 42 5 42 5 0.74
White blood cell, 103 ml 7.5 2.1 7.2 2.0 0.54
[Na], mmol/l 139 3 139 4 0.24
[K], mmol/l 4.3 0.4 4.4 0.4 0.14
BUN, mg/dl 21 17 25 13 0.03
Creatinine, mg/dl 1.4 0.7 1.4 0.5 0.09
Digoxin 1%, nmol/l 75 70 0.6
Digoxin 1%, nmol/l 25 30 0.6
 arterial blood; AHI  apnea-hypopnea index; BUN  blood urea nitrogen; DLCO  diffusingp
apacity for CO; FEV1  forced expiratory volume in 1 s; FVC  forced vital capacity; P  partial
ressure.ransplantation with death as the primary end point. Most
tudies only reported limited variables, making it difficult to
ssess the effects of confounders on survival. Inclusion of
atients with obstructive sleep apnea with CSA in some
tudies has resulted in homogeneity, making it difficult to
nterpret the results. In some studies full polysomnography
as not performed.
The strength of the present study includes performing
ull night polysomnography after a night of habituation,
coring of sleep studies blindly by 1 investigator who also
xamined all patients, availability of a large number of
aboratory studies on the day of polysomnography, and
nalysis of a variety of factors that could affect survival of
F patients. In the univariate analysis, low LVEF (p 
.004), NYHA functional class III (p  0.003), heart rate
p  0.03), and high serum digoxin (p  0.007) were
ignificantly correlated with low probability of survival.
herefore, these results are in agreement with studies that
how low LVEF and high NYHA functional class and
igoxin level (20) contribute to mortality. Yet, in Cox
roportional hazard multiple regression analysis, CSA,
VEF, and diastolic blood pressure were the only 3 inde-
endent predictors of survival. In regard to the mechanism
f CSA’s effect on mortality, we suggest that the composite
onsequences of apnea (6,7) including desaturation, arous-
ls, and increased negative intrathoracic pressure (during
yperpnea that follows central apnea) adversely affect car-
iac function and contribute to excess mortality in HF.
The results of the present study showing that RVEF is an
ndependent predictor of mortality are in agreement with
he results of several previous studies (21–28). One of the
ajor determinants of right ventricular systolic function is
Heart
Sleep Apnea
HI <5/h AHI >5/h p Value
32 56
2.2 1 35 25
0.6 0.9 23 22
0.1 0.2 0.5 1.4
2 1 32 25
0.2 0.5 1 2
00 32 391 18 0.03
88 67 270 54 0.17
34 24 38 25 0.2
46 23 46 23 0.5
0.8 2 0.5 2 0.3
20 9 16 11 0.03
80 9 84 11 0.03
15 10 26 18 0.003
95 2 95 2 0.4
89 4 82 11 0.0001
1 4 11 17 0.0001pnea
n 88
ntral
A
4
2ulmonary artery pressure (28). In the context of the results
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Sleep Apnea and Mortality in HF May 22, 2007:2028–34f the present study, this is important, because it is likely
hat patients with sleep apnea and nocturnal desaturation
ad more severe pulmonary arterial hypertension (sustained
r intermittent), which could have resulted in further
mpairment in right ventricular function. We also found
hat low diastolic blood pressure was a predicator of poor
urvival. This is consistent with the results of the Framing-
am study (29) showing that from 60 years on diastolic
lood pressure negatively correlated with coronary heart
isease and mortality. Because diastolic blood pressure is a
ajor determinant of coronary blood flow, a low diastolic
ressure could result in myocardial ischemia particularly
uring sleep. Normally during non–rapid-eye-movement
leep, diastolic blood pressure decreases. This could be the
ain factor contributing to non-demand myocardial ischemia
uring sleep that has a nadir between 1:00 AM and 3:00 AM
30). We therefore suggest that low diastolic blood pressure
n conjunction with apnea-induced desaturation might con-
ribute to myocardial ischemia and perhaps also to nocturnal
rrhythmias, because HF patients with CSA have more
entricular arrhythmias during sleep than those without
nivariate Analysis for Survival Time and 24 Relatedariables in 88 Patients With Systoliceart Failure
Table 4
Univariate Analysis for Survival Time and 24
Related Variables in 88 Patients With Systolic
Heart Failure
Variable Hazard Ratio 95% CI p Value
Age, yrs 1.02 (0.99–1.05) 0.14
BMI, kg/m2 0.94 (0.89–0.99) 0.04
HR, beats/min 1.09 (1.002–1.037) 0.03
SBP, mm Hg 0.981 (0.968–0.995) 0.006
DBP, mm Hg 0.963 (0.938–0.989) 0.006
Smoking — — 0.34
NYHA functional class* — — 0.003
LVEF, % 0.96 (0.93–0.99) 0.004
RVEF, % 0.96 (0.94–0.98) 0.0002
Atrial fibrillation — — 0.69
Ischemic vs. idiopathic — — 0.35
AHI, n/h — 0.01
Min. SaO2, % 0.971 (0.949–0.993) 0.01
SaO2 90%, min 1.007 (1.001–1.013) 0.03
FEV1, % 0.997 (0.984–1.01) 0.66
FVC, % 0.988 (0.973–1.003) 0.10
FEV1/FVC, % 1.017 (0.996–1.039) 0.11
DLCO 0.982 (0.968–0.996) 0.01
PaO2, mm Hg 1.005 (0.984–1.027) 0.62
PaCO2, mm Hg 0.923 (0.863–0.988) 0.02
K, mmol/l 1.372 (0.74–2.545) 0.32
Na, mmol/l 0.955 (0.874–1.044) 0.31
Hemoglobin, g% 0.859 (0.742–0.995) 0.04
Digoxin,† nmol/l — — 0.007
azard ratios, 95% confidence intervals, and p values are reported for continuous variables; only p
alues are reported for categorical variables. *Patients with New York Heart Association (NYHA)
unctional class III had the shortest median survival time when compared with patients with class
and II combined. †Patients with digoxin level 1 had longer median survival time than patients
ith digoxin level 1 nmol/l.
CI confidence interval; DBP diastolic blood pressure; HR heart rate; LVEF left ventricular
jection fraction; NYHA  New York Heart Asssociation; RVEF  right ventricular ejection fraction;
BP  systolic blood pressure; other abbreviations as in Tables 1 and 3.SA (2).Previous studies (31–35) show that obstructive sleep
pnea contributes to mortality. Therefore, it is not surpris-
ng that this study shows that, in patients with established
F, CSA also contributes to mortality.
Our study suffers from a number of limitations. Many
ther variables that might affect survival of HF patients were
ot available for analysis, and like most previous studies of
leep apnea in HF (8–13), only a few patients were taking
eta blockers (when the study began, beta-blockers were not
et part of standard therapy). Beta-blockers, by improving
ardiovascular function, might improve sleep apnea and
urvival, but studies to ascertain effect of CSA in patients
ith HF taking beta blockers are lacking. Another major
imitation of the present study was lack of knowledge
egarding use and compliance with supplemental nocturnal
xygen, which was recommended only for patients with
HI 15/h. Therefore we can’t be certain whether use of
xygen affected survival. However, because we found de-
reased median survival time of patients with higher AHI
han lower AHI across various cutoff points (Fig. 2), our
ata suggest that sleep apnea by itself is a major predictor of
urvival in HF.
The important question is whether the effective treatment
f CSA is associated with improved survival. Therapeutic
ptions (6,7) to treat CSA include nocturnal administration
f supplemental nasal oxygen (36), theophylline (37), acet-
zolamide (38), and use of positive airway pressure devices
39,40). Among these, only continuous positive airway
ressure (CPAP) has been tested for survival (39). This
ulticenter study (39) was prematurely terminated in part
ecause of increased early mortality of patients in the CPAP
rm. However, the high mortality might have been due to
dverse hemodynamic effects of CPAP, particularly in those
atients who were non-responsive to CPAP (41). Because
Figure 1 CSA is a Predictor of Mortality in Systolic HF
Survival of heart failure (HF) patients with or without central sleep apnea
(CSA) after accounting for all other confounders. AHI  apnea-hypopnea index.
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May 22, 2007:2028–34 Sleep Apnea and Mortality in HFPAP results in increased intrathoracic pressure, it could
ecrease venous return, adversely affecting right ventricular
troke volume, causing hypotension, decreased coronary
lood flow, and myocardial ischemia. Therefore, in some
atients with HF, treatment with CPAP might further
dversely affect central hemodynamic status. This is inter-
sting in the context of the present study, because we found
hat right ventricular dysfunction and low diastolic blood
ressure are predictors of poor survival patients. Other
herapeutic modalities (6,7) such as supplemental oxygen that
re devoid of adverse hemodynamic effects could improve
urvival, yet no long-term study has been done (42).
In summary, the results of this study show that presence
f CSA is associated with poor survival in patients with
ystolic HF. This association remained strong after adjust-
ents for a number of known pathophysiological factors
hat have generally been considered to be major predictors
f poor survival in patients with systolic HF.
eprint requests and correspondence: Dr. Shahrokh Javaheri,
ulmonary Section (111F), VA Medical Center, Cincinnati, Ohio
5220. E-mail: Javaheri@snorenomore.com.
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